(Q45389693)

14 December 2017

A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection (English)

1 reference

14 December 2017

1 reference

1 reference

Jean-Michel Pawlotsky

6

1 reference

14 December 2017

9

1 reference

14 December 2017

12

1 reference

14 December 2017

7

Stefan Zeuzem

1 reference

14 December 2017

4

Asa Alsiö

0 references

DITTO-HCV Study Group

13

object named as

DITTO-HCV Study Group

1 reference

14 December 2017

1

Johan Westin

1 reference

14 December 2017

8

Solko W Schalm

1 reference

14 December 2017

2

Magdalena Ydreborg

1 reference

14 December 2017

5

Amar P Dhillon

1 reference

14 December 2017

Sara Islam

3

1 reference

14 December 2017

Asa Alsiö

4

1 reference

14 December 2017

Avidan U Neumann

10

1 reference

14 December 2017

Kristoffer Hellstrand

11

1 reference

14 December 2017

1 January 2008

1 reference

Scandinavian Journal of Gastroenterology

14 December 2017

1 reference

14 December 2017

43

1 reference

14 December 2017

1

1 reference

14 December 2017

73-80

1 reference

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

14 December 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Progression of fibrosis in untreated patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520701514461

10.1080/00365520701514461

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference